By Robert Michel, from the Volume XXV No. 15 – October 22, 2018 issue
In a time of shrinking lab budgets and falling prices for lab tests in the United States, how are the larger in vitro diagnostic (IVD) manufacturers doing? A look at third-quarter financial reports provides useful insights as to which segments within the IVD industry are doing better than others.
In alphabetical order, here’s a quick snapshot
By Joseph Burns, from the Volume XIX No. 14 - October 8, 2012 issue
CEO SUMMARY: Danaher Corporation continues to fuel growth by continually acquiring in vitro diagnostics (IVD) companies. Its latest purchase is Iris International, which manufactures automated urine microscopy systems. Danaher also has $5 billion available that it could spend in the next two years on acquisitions. Because of its acquisitions over the past decade, Danaher now
By Robert Michel, from the Volume XVII No. 13 - September 13, 2010 issue
Researchers at North Carolina State University are developing a method that might make it possible to diagnose and treat cancer through the use of special microneedles they developed. NCSU researchers use the microneedles to deliver nanoscale dyes based on quantum dots to locations under the skin. “Our findings are significant, in part, because this technology
By Robert Michel, from the Volume XVI No. 4 - March 16, 2009 issue
CEO SUMMARY: For Beckman Coulter, the opportunity to acquire the diagnostics business of Olympus Corporation was compelling for at least two reasons. One, the chemistry and automation products of both companies are quite complementary. Two, in a steadily-consolidating in vitro diagnostics (IVD) industry, Beckman’s acquisition of the Olympus diagnostics unit was an important strategic response.
By Robert Michel, from the Volume XIV No. 17 - December 10, 2007 issue
CEO SUMMARY: As it turns out, 2007 has been an action-packed year with lots of events, plenty of changes, and the promise of even faster evolution across all sectors of the lab testing marketplace. THE DARK REPORT’S “Top Ten Lab Stories of 2007” show the full intensity and pace of activity within laboratory medicine. One big driver in
By Robert Michel, from the Volume XIV No. 11 - August 6, 2007 issue
CEO SUMMARY: Misys Healthcare Systems of London, England, has sold its diagnostic LIS systems to Vista Equity Partners of San Francisco, California, for $381.5 million. The deal raises several questions, particularly for those labs currently running Misys laboratory information systems (LIS). Will the new owner make the substantial investment required to upgrade the LIS and
By Robert Michel, from the Volume XIV No. 11 - August 6, 2007 issue
CEO SUMMARY: In just 15 months, Siemens AG has pulled out its checkbook three times to spend more than $14 billion to acquire major in vitro diagnostics (IVD) companies. When it closes the purchase of Dade Behring, Siemens will be in the first rank of global IVD manufacturers. It has also declared that it is
By Robert Michel, from the Volume XIV No. 10 - July 16, 2007 issue
CEO SUMMARY: Both companies have said little about their mutual decision, announced last week, to kill the pending sale of Abbott Diagnostics and Point-of-Care businesses to General Electric. One probability is that GE decided, during due diligence, that its willingness to pay a premium price—15 times EBIDTA—was unjustified by the quality of the assets and
By Robert Michel, from the Volume XIV No. 9 - June 25, 2007 issue
“The Web has transformed many industries and it’s clearly affected our industry. This trend will help raise the bar in quality and overall performance among laboratories and manufacturers.”
—Jim Reid-Anderson
Chairman, President, and CEO of Dade Behring
CEO Summary: Recently, THE DARK REPORT conducted a roundtable interview with executives of Dade Behring. Present were Jim Reid-Anderson, Chairman, President
By Robert Michel, from the Volume XIV No. 5 - April 2, 2007 issue
CEO SUMMARY: Biggest deal in recent weeks was the $1.55 billion Beckman Coulter paid to acquire BioSite and its Triage BNP test. But the most interesting news may be the entry of 3M Corporation into clinical diagnostics, based on its acquisition of Acolyte Biomedica Ltd., a company which offers a five-hour rapid culture-based MRSA test.
